Literature DB >> 14742182

Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Markus Mueller1, Amparo de la Peña, Hartmut Derendorf.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14742182      PMCID： PMC321563          DOI： 10.1128/AAC.48.2.369-377.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  117 in total

1.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

2.  Pharmacokinetic-pharmacodynamic model for spiramycin in staphylococcal mastitis.

Authors:  L Renard; P Sanders; M Laurentie; J M Delmas
Journal:  J Vet Pharmacol Ther       Date:  1996-04       Impact factor: 1.786

3.  An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.

Authors:  S M Palmer; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-04       Impact factor: 5.790

4.  An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

5.  Two compartment kinetic model with multiple artificial capillary units.

Authors:  J Blaser; B B Stone; S H Zinner
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models.

Authors:  S Keil; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

Review 9.  Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA.

Authors:  W A Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

10.  Potential impact of quantitative susceptibility tests on the design of aminoglycoside dosing regimens.

Authors:  J P McCormack; J J Schentag
Journal:  Drug Intell Clin Pharm       Date:  1987-02
View more
  91 in total

1.  Enhancement of the enterocin CRL35 activity by a synthetic peptide derived from the NH2-terminal sequence.

Authors:  Lucila Saavedra; Carlos Minahk; Aída P de Ruiz Holgado; Fernando Sesma
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  The bacterial surface layer provides protection against antimicrobial peptides.

Authors:  César de la Fuente-Núñez; Jan Mertens; John Smit; Robert E W Hancock
Journal:  Appl Environ Microbiol       Date:  2012-05-25       Impact factor: 4.792

4.  [Therapy concepts for septic diseases].

Authors:  R Wildenauer; C T Germer
Journal:  Chirurg       Date:  2010-05       Impact factor: 0.955

5.  Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.

Authors:  M Andraud; C Chauvin; P Sanders; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

6.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation.

Authors:  Maurice J Ahsman; Enno D Wildschut; Dick Tibboel; Ron A Mathot
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

7.  Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations.

Authors:  C Wiuff; R M Zappala; R R Regoes; K N Garner; F Baquero; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.

Authors:  Johan W Mouton; Nieko Punt; Alexander A Vinks
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Authors:  Felipe K Hurtado; Benjamin Weber; Hartmut Derendorf; Guenther Hochhaus; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

10.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.